A Review of Nanoparticles Toxicity and Their Routes of Exposures Transdermal delivery of insulin
Iranian Journal of Pharmaceutical Sciences,
Vol. 8 No. 1 (2012),
15 January 2012
,
Page 299-314
https://doi.org/10.22037/ijps.v8.41001
Abstract
The new scientific innovation of engineering nanoparticles (NPs) at the atomic scale (diameter<100nm) has led to numerous novel and useful wide applications in electronics, chemicals, environmental protection, medical imaging, disease diagnoses, drug delivery, cancer treatment, gene therapy, etc.. The manufactures and consumers of the nanoparticles-related industrial products, however, are likely to be exposed to these engineered nanomaterials which have various physical and chemical properties at levels far beyond ambient concentrations. These nanosized particles are likely to increase unnecessary infinite toxicological effects on animals and environment; although their toxicological effects associated with human exposure are still unknown. To better understand the impact of these exposures on health, and how best to formulate appropriate monitoring and control strategies, this review seeks to examine various toxicological portal routes associated with NPs exposures. In fact, these ultrafine particles are capable of entering the body through skin pores, debilitated tissues, injection, olfactory, respiratory and intestinal tracts. These uptake routes of NPs may be intentional or unintentional. Their entry may lead to
various diversified adverse biological effects. Until a clearer picture emerges, the limited data available suggest that caution must be exercised when potential exposures to NPs are encountered. Some methods have been used to determine the portal routes of nanoscale materials on experimental animals. They include pharyngeal instillation, injection, inhalation, cell culture lines and gavage exposures.
This review also provides a step by step systematic approach for the easy identification and addressing of occupational health hazards arising from NPs.
- Exposure
- Nanoparticles
- Toxicity
How to Cite
References
[2] Stern ST, McNeil ES. Nanotechnology safety concerns revisited. Toxicol Sci 2008; 101: 4-21.
[3] Jiale H, Qingbiao L, Daohua S, Yinghua L, Yuanbo S, Xin Y, Huixuan W, Yuanpeng W, Wenyao S, Ning H, Jinqing H, Cuixue C. Biosynthesis of silver and gold NPs by novel sundried Cinnamomum camphora leaf.
Nanotechnology 2007; 18: 105104.1-11
[4] Sadowski Z, Maliszewska IH, Grochowalska B, Polowczyk I, Koźlecki T. Synthesis of silver NPs using microorganisms. Mater Sci Poland 2008; 26: 419-24.
[5] Maynard AD, Kuempel E. Airborne nanostructured particles and occupational health.J Nanopart Res 2005; 7: 587-614.
[6] Donaldson K, Aitken R, Lang T, Vicki S, Rodger D, Gavin F, Andrew A. Carbon nanotubes: a review of their properties in relation to pulmonary toxicology and workplace safety. Toxicol Sci 2006; 92: 5-22.
[7] Peter HH, Irene BH, Oleg VS. Nanoparticles: known and unknown health risks. J Nanobiotechnocol 2004; 2: 12
[8] Oberdörster G, Oberdörster E, Oberdörster J.Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005; 113: 823-39.
[9] Chen Z, Huan M, Gengmei X, Chunying C, Yuliang Z, Guang J, Tiancheng W, Hui Y, Feng Z, Zhifang C, Chuannfeng Z, Xiaohong F, Baocheng M, Lijun W. Acute toxicological effects of copper nanoparticles in vivo. Toxicological Letters 2006; 163: 109-20.
[10] Mayank DB, Mansoor MA. Gastrointestinal distribution and in vivo gene transfection studies with NPs-in-microsphere oral system (NiMOS). J Controlled Release 2007; 119: 339-48.
[11] Ku BK, Maynard AD. Comparing aero¬sol surface-area measurements of monodis¬perse ultrafine silver agglomerates by mobility analysis, transmission electron microscopy and diffusion charging. J Aerosol Sci 2005; 36: 1108-24.
[12] Warheit DB, Laurence BR, Reed KL, Roach DH, Reynolds GAM, Webb TR. Comparative pulmonary toxicity assessment of single-wall carbon nanotubes in rats. Toxicol Sci 2004; 77: 117-25.
[13] Beck-Speier I, Dayal N, Karg E, Maier KL, Schumann G, Schulz H, Semmler M, Takenaka S, Stettmaier K, Bors W. Oxidative stress and lipid mediators induced in alveolar macrophages by ultrafine particles. Free Radical Biol Med 2005; 38: 1080-92.
[14] Borm PJ, Kreyling W. Toxicological hazards of inhaled nanoparticles: potential implications for drug delivery. J Nanosci Nanotechnol 2004; 4: 521-31.
[15] Cross SE, Innes B, Roberts MS, Tsuzuki T, Robertson TA, McCormick P. Human skin penetration of sunscreen nanoparticles: in vitro assessment of a novel micronized zinc oxide formulation. Skin Pharmacol Physiol 2007; 20:148-54.
[16] Lam CW, James JT, McCluskey R, Arepalli S, Hunter RL. A review of carbon nanotube toxicity and assessment of potential and environmental health risks. Crit Rev Toxicol 2006; 36: 189-217.
[17] IRSST- Nanoparticles. Actual knowledge about occupational health and safety risks and prevention measures. 2006; R-470
[18] Dreher KL. Health and environmental impact of nanotechnology: toxicological assessment of manufactured NPs. Toxicol Sci 2004; 77: 3-5.
[19] Seaton A, Donaldson K. Nanoscience, nanotoxicology, and the need to think small. Lancet 2005; 365: 923-4.
[20] Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, Radomski MW. Nanoparticles: pharmacological and toxicological significance. British J Pharmacol 2007; 150: 552-8.
[21] ISO. Workplace atmospheres: ultrafine, nanoparticle and nano-structured aerosolsexposure characterization and assessment. Geneva: Switzerland: International Standards Organization. 2006; Document no. ISO/TC 146/SC 2/WG1 N324, p. 32.
[22] Murr LE, Esquivel EV, Bang JJ. Characterization of nanostructure phenomena in airborne particulate aggregates and their potential for respiratory health effects. J Mater Sc Mater Med 2004; 15: 237-47.
[23] Li Z, Hulderman T, Salmen R, Chapman R, Stephen SL, Shih-Houng Y, Shvedova A, Luster MI, Simeonova PP. Cardiovascular effects of pulmonary exposure to single-wall carbon nanotubes. Environ Health Perspect 2007; 115: 377-82.
[24] Davoren M, Herzog E, Casey A, Benjamin C, Gordon C, Hugh JB, Fiona ML. in vitro toxicity evaluation of single walled carbon nanotubes on human A549 lung cells. Toxicol in vitro 2007; 21:438-48.
[25] De Jong WH, Hagens WI, KrystekP, Burger MC, Sips AJAM, Geertsma RE. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 2008; 29: 1912-9.
[26] Jeffrey WC, Zeldin DC, Bonner JC, Nestmann RE. Pulmonary applications and toxicity of engineered nanoparticles. Am J Physiol Lung Cell Mol Physiol 2008; 1-55.
[27] Auffan M, Achouak W, Rose J, Chane´C, Waite DT, Masion A, Woicik J,Wiesner MR, Bottero JY. Relation between the redox state of ironbased nanoparticles and their cytotoxicity towards Escherichia coli. Environ Sci Technol 2008; 42: 6730-5.
[28] Geiser M, Casaulta M, Kupferschmid B, Schulz H, Semmler-Behnke M, Kreyling W.. The role of macrophages in the clearance of inhaled ultrafine titanium dioxide particles. Am J Respir Cell Mol Biol 2008; 38: 371-6.
[29] ICRP. Human respiratory tract model for radiological protection. Oxford, England: Pergamon, Elsevier Science Ltd., International Commission on Radiological Protection 1994. Publication No. 66.
[30] Daigle CC, Chalupa DC, Gibb FRMorrow PE, Oberdorster G, Utell MJ, Frampton MW. Ultrafine particle deposition in humans during rest and exercise. Inhalation Toxicol 2003; 15: 539-52.
[31] Berry JP, Arnoux B, Stanislas G, Galle P, Chretien J. A microanalytic study of particles transport across the alveoli: role of blood platelets. Biomedicine 1977; 27: 354-7.
[32] Ballou B, Lagerholm BC, Ernst LA, Bruchez MP, Waggoner AS. Non-invasive imaging of quantum dots in mice. Bioconjugate Chem 2004; 15: 79-86.
[33] Gwinn MR, Vallyathan V. Nanoparticles: Health Effects: Pros and Cons. Environ Health Perspect 2006; 114: 1818-25.
[34] Yakovenko ML, Ekaterina AK, Olga EI, Tatyana PE, Samoilovich E, Iryna U, Gene VG, Vadim IA. Evolution of the sabin vaccine into pathogenic derivatives without appreciable changes in antigenic properties: need for improvement of current poliovirus surveillance. J Virol 2009; 83: 3402-6.
[35] Flesken AN, Toshkov INJ, Katherine MT, Rebecca MW, Warren RZ, Giannelis MP, Nikitin AY. Toxicity and biomedical imaging of layered nanohybrids in the mouse. Toxicol Pathol 2007; 35: 804-10.
[36] De Lorenzo AJD. The olfactory neuron and the blood–brain barrier. In: Wolstenholme, G.E.W., Knight, J. (Eds.), Taste and Smell in Vertebrates. CIBA Foundation Symposium Series. J. & A. Churchill, London 1970; pp. 151-76.
[37] Jani PU, Halbert GW, Langridge J, Florence AT. NPs up take by the rat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm Pharmacol 1990; 42: 821-6.
[38] Yoshifumi T. Lipid formulation as a drug carrier for drug delivery. Curr Pharm Des 2002; 467-74.
[39] Hussain N, Vikas J, Alexander TF. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv Drug Delivery Rev 2001; 50:107-42.
[40] Blundell G, Henderson WJ, Price EW. Soil particles in the tissue of the foot in endemic elephantiasis of the lower legs. Ann Trop Med Parasitol 1989; 83: 381-5.
[41] Monteiro-Riviere NA. In: Zhai, H.,Wilhelm, K.P., Maibach, H.I. (Eds.). Anatomical factors that affect barrier function. CRC Press, New York, NY, 2008; pp. 39-50.
[42] Kim S, Lim YS, Soltesz EG, De Grand AM, Lee J, Nakayama A, Parker JA, Mihaljevic T, Laurence RG, Dor DM, Cohn LH, Bawendi MG, Frangioni JV. Near infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol 2004; 22: 93-7.
[43] Tinkle SS, Antonini JM, Rich BA, Robert JR, Salmen R, DePree K, Adkins EJ. Skin as a route of exposure and sensitization in chron¬ic beryllium disease. Environ Health Perspect 2003; 111: 1202-8.
[44] Zhang WL, Yu WW, Vicki LC, Monteiro-Riviere NA. Biological interactions of quantum dot NPs in skin and in human epidermal keratinocytes. Toxicol Appl Pharmacol 2008; 228: 200-11.
[45] Ryman-Rasmussen J, Riviere JE, Monteiro-Riviere NA. Surface coatings determine cytotoxicity and irritation potential of quantum dot NPs in epidermal keratinocytes. J Invest Dermatol 2007; 127: 143-53.
[46] Tan MH, Commens CA, Burnett L, Snitch PJ. A pilot study on the percutaneous absorption of microfine titanium dioxide from sunscreens. Australas J Dermatol 1996; 37: 185-7.
[47] Rodney FS, Barbara LE. Bacteria of porcine skin, xenografts, and treatment with neomycin sulfate. Appl Microbiol 1972; 23: 293-7.
[48] Baroli B. Nanoparticles and skin penetration. Are there any potential toxicological risks? J Verbr Lebensm 2008; 3: 330-1.
[49] Aniruddha CA, Surya PA, Uday BK. Ocular distribution of intact nano- and microparticles following subconjunctival and systemic routes of administration. Drug Delivery Technol 2008; 3.
[50] Jarvinen K, Jarvinen T, Urtti A. Ocular absorption following topical delivery. Adv Drug Del Rev 1995; 16: 3-19.
[51] Herrero-Vanrell R, Refojo MF. Biodegradable microspheres for vitreoretinal drug delivery. Adv Drug Delivery Rev 2001; 52: 5-16.
[52] Farjo F, Skaggs J, Quiambao AB, Cooper MJ, Naash MI. Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. PLOS ONE 2006; 1: e38. doi:10.1371/journal.pone.0000038
[53] Jani PD, Singh N, Jenkins C, Raghava S, Mo Y, Amin S, Uday BK, Balamurali KA. Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis.
Invest Ophthalmol Vis Sci 2007; 48: 2030-6.
[54] Mamedova N, Dormer K, Kopke R, Chen K, Liu J, Ronald J, Costello M. Gibson D, Mondalek F. Feasibility of superparamagnetic NPs for drug delivery to the inner ear. 2005; http://www.nanobmi.com/images/Abstract_Nano_2005.pdf
[55] Xianxi G, Ronald J, Jianzhong L, Balough B, Hoffer ME. Distribution of polylactic/glycolic acid (PLGA) NPs in Chinchilla Cochlea. The 13th Annual Midwinter Research Meeting of the Association for research In otolaryngology, Denver, Colorado, USA, February,10-15, 2007.
[56] Barnes AL, Wassel RA, Mondale F, Chen K, Dormer KL, Kopke RD. Magnetic characterization of superparamagnetic nanoparticles pulled through model membranes. Biomagn Res Technol 2007; 5: 1.
[57] Rocio FU, Fattal E, Fbger J, Couvreur P, Thond P. Evaluation of hepatic antioxidant systems after intravenous ahministration of polymeric NPs. Biomoteriols 1997; 18: 511-7.
[58] Thanos C, Sandor M, Jong Y, Jacob J, Yip KP, Harper J, Morrell C, Scherer J, Mathiowitz E. Inter-species uptake of polymeric particles. Mater Res Soc Symp Proc 1999; 550: 65-70.
[59] Moghimi SM, Hunter AC, Murray JC. Longcirculating and targetspecific NPs: theory to practice. Pharmacol Rev 2001; 53: 283-318.
[60] Umamaheshwari RB, Ramteke S, Jain NK. Anti-Helicobacter Pylori effect of mucoadhesive NPs bearing amoxicillin in experimental gerbils model. AAPS Pharm Sci Tech 2004; 5:32-6.
- Abstract Viewed: 203 times
- IJPS_Volume 8_Issue 1_Pages 299-314 Downloaded: 65 times